

Big data for blood cancer:
HARMONY can accelerate your research to benefit patients with Hematologic Malignancies.

Find out how! →

The HARMONY Alliance uses big data analytics to accelerate the development of personalized treatments for patients with Hematologic Malignancies. HARMONY is a unique partnership of more than 80 public, private and patient organizations, funded by the Innovative Medicines Initiative.

HARMONY researchers are already mining the unique HARMONY
Big Data Platform to address pressing research questions in ALL, AML,
CLL, MDS, NHL, MM, and pediatric HMs. Please join us in this large
European endeavor to improve the care for blood cancer patients.

- Attend the HARMONY Session

  Saturday, 15 June 2019 | Hall E106 | 14:45-16:15 hrs.
- Join the HARMONY Partnering Meeting
  Saturday, 15 June 2019 | Room D201 | 16:15-17:45 hrs.
- Visit the HARMONY booth in the EHA Collaboration Plaza at the exhibition.

### Did we trigger your interest? Let's connect!

We look forward to presenting our ongoing research projects, explaining how data quality, safety, and privacy are ensured, and showing that we are developing core outcome sets.

More importantly, we would like to discuss how your research may benefit from HARMONY and how you can contribute. We are eager to welcome you as a new Associated Member of our network!

#bigdataforbloodcancer

# Big Data to Enable Better and Faster Treatments for Patients with Hematologic Malignancies

#### The HARMONY Alliance:

European Network of Excellence for Big Data in Hematology: currently 53 Partners and 35 Associated Members from 22 European countries.

A public-private partnership funded by the Innovative Medicines Initiative. 2017-2021.



## The HARMONY Big Data Platform:

Captures 45,000 data records from European blood cancer patients in 2019 and will expand to 100.000 sets by 2021. Includes diagnostics, genomics, treatment choices, and outcomes collected by Partners and Associated Members. Focus on ALL, AML, CLL, MDS, MM, NHL and Pediatric HM.

## www.harmony-alliance.eu











# The HARMONY Anonymization Concept

Ensures that the intended import of data, as well as the subsequent use of such data as envisaged by HARMONY, comply with ethical guidelines and all applicable EU data protection laws (GDPR), without impacting the clinical value of the relevant data.


HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

# Algorithms to transform knowledge into better medicine outcomes

HARMONY focus - 7 HMs: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies.

## www.harmony-alliance.eu/en/research-projects

Check out our current projects, more to follow.





What are the most important outcomes for AML, according to patients, clinicians, health authorities, and the pharmaceutical industry?

What is the best way to prevent and manage complications of APL treatment?

How do mutations in 11 of the most frequently mutated genes in CLL correlate to prognosis and treatment response? Which subgroups of MDS patients benefit from treatment with hypomethylating agents?





PARTNERS: Abbvie, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) | Amgen | Assistencie Publique-Hopitaux de Paris (AP-HP) | Barts Health NHS Trust | Bayer AG | BFArM Bundesinstitut für Arzneimittel und Medizinprodukte | Celgene | Charité – Universitätsmedizin | Berlin | EAPM (European Alliance for Personalised Medicine) | ELN Foundation | ECNTC (European Group for Blood and Arnew Transplantation | European Hematology Association (EHA) | FisMonlus Fondazione Italiana Sindromi | Flanders Institute of Biotecnology (VIB) | Genome Research Limited (GRL-SANGER) | German Society of Pediatric Onco-hema (GPOH) | GMV Soluciones (GPOH) | GM